Do elevated thyroid peroxidase antibodies indicate autoimmune thyroid dysfunction?

Elevated thyroid peroxidase (TPO) antibodies serve as a key clinical marker of immune-mediated destruction of the thyroid gland, leading to systemic metabolic and inflammatory consequences.

Immunopathology and clinical significance

• Targeted thyrocyte destruction: Elevated TPO antibodies, specifically IgG1 and IgG3 subclasses, bind to the apical surface of thyrocytes. This initiates complement-dependent cytotoxicity (CDC) via C1q activation and drives antibody-dependent cell-mediated cytotoxicity (ADCC) through natural killer cells and macrophages, resulting in progressive follicular damage and lymphocytic infiltration.
• Diagnostic and prognostic utility: TPO antibodies are highly sensitive, appearing in 90% to 95% of Hashimoto's thyroiditis cases. In biochemically euthyroid individuals, elevated TPO antibodies represent a significant risk factor, multiplying the annual risk of progression to overt hypothyroidism five- to eight-fold.

Systemic and metabolic impacts

• Neuroinflammatory fatigue: Elevated TPO antibodies stimulate the chronic release of systemic pro-inflammatory cytokines, specifically IL-6 and TNF-alpha. These cytokines interact with the central nervous system to drive the persistent clinical fatigue and cognitive deficits frequently observed in autoimmune thyroiditis.
• Atherogenic lipid profiles: Even when patients are biochemically euthyroid, autoimmune thyroiditis is associated with elevated total cholesterol, LDL-C, triglycerides, and lipoprotein(a). This is driven by localized hepatic thyroid hormone deficits that downregulate LDL receptor expression, thereby slowing the systemic clearance of circulating lipids.
• Impaired metabolic resilience: Reduced tissue-level thyroid hormone sensitivity and impaired T4-to-T3 conversion—often linked to deiodinase polymorphisms like Thr92Ala in DIO2—cause localized tissue hypothyroidism. This reduces resting energy expenditure and metabolic rate in key tissues like liver and skeletal muscle, lowering overall metabolic adaptability.

Bottom line

• Elevated TPO antibodies drive direct autoimmune destruction of thyroid tissue and trigger chronic systemic inflammation and localized, tissue-level thyroid hormone resistance. These pathways explain why patients frequently experience persistent fatigue, adverse lipid profiles, and reduced metabolic resilience, even when routine serum TSH and free T4 levels remain within normal reference ranges.